-
Anti-CA19-9/Sialyl Lewis A (sLeA) Antibody FL650 Conjugate
Anti-CA19-9/Sialyl Lewis A (sLeA) Antibody FL650 Conjugate
- 中文名称：
- Anti-CA19-9/Sialyl Lewis A (sLeA) Antibody FL650 Conjugate
- 英文名称：
- Anti-CA19-9/Sialyl Lewis A (sLeA) Antibody FL650 Conjugate
- 品牌：
- Antibodies Inc
- 品牌介绍：
- Antibodies Inc.成立于1962年， 在神经科学领域备受推崇，拥有针对关键神经科学靶点的一流小鼠单克隆抗体。最初专注于二抗和免疫测定，在2005年，与加州大学戴维斯分校和美国国立卫生研究院合作，成为高度验证的NeuroMab系列小鼠单克隆抗体的商业供应商。这些高品质的抗体经过全部测试，数十种已进行基因敲除验证，并提供四种不同荧光标记物的抗体。我们的定制抗体服务提供量身定制的解决方案，包括单克隆和多克隆选项，以及生产、共轭和免疫测定服务。所有这些工作都在位于加利福尼亚州戴维斯的ISO-13485认证设施中完成。
- 货号：
- MM-1003-FL650
- 规格：
- 200 µL
- 保存建议：
- 分装后于 ≤ -20°C 长期储存；短期储存可保存于 2–8°C。为最大限度回收产品，请在打开瓶盖前先离心试剂瓶。
- 背景资料：
- CA19-9/ Sialyl Lewis a (sialyted lacto-N-fucopentose) (α-NeuNAc-(2→3)-β-D-Gal-(1→3)-(α-L-Fuc-[1→4])-D-GlcNAc, 3′-SLea) corresponds to blood group antigens. In normal tissue Sialyl Lewis a is present in ductal epithelium of the breast, kidney and salivary glands. This antigen is expressed is increased in all gastrointestinal carcinomas (stomach, intestine and pancreas) (1) While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring (3) Other causes for elevated CA19-9 levels include Mirizzi’s syndrome and other hepatobiliary diseases (2) In patients that do not have the Lewis antigen blood type (about 5% of the population), CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9 (1).
- 货期：
- 4-6周
- 来源宿主：
- Mouse
- 反应种属：
- Human
- 应用：
- IHC, ICC
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
免疫原物种：Human
克隆性：Monoclonal
克隆号：CA19-9-203
浓度：0.5 mg/mL
分子量：120-400 kDa
- 说明书：
Our Anti-CA19-9/Sialyl Lewis A (sLeA) mouse monoclonal primary antibody from Antibodies Incorporated is produced in-house from hybridoma clone CA19-9-203. It detects human CA19-9/Sialyl Lewis A (sLeA), and is purified by protein a chromatography. It is great for use in IHC, ICC.
